Overview
To assess the efficacy and safety of Intravascular Lithotripsy (IVL) in subjects undergoing transfemoral TAVR in patients with severe iliac disease, prohibitive for transfemoral TAVR in patients with severe symptomatic aortic stenosis, otherwise considered for alternative access TAVR. (e.g. trans-carotid)
Description
The goal of this post-market, prospective, observational single-arm cohort study is to assess the efficacy and safety of Intravascular Lithotripsy (IVL) in subjects undergoing transfemoral TAVR in patients with severe iliac disease, prohibitive for transfemoral TAVR in patients with severe symptomatic aortic stenosis, otherwise considered for alternative access TAVR. (e.g. trans-carotid). This is a study of patients referred to BSW The Heart Hospital, Plano for evaluation of critical aortic stenosis. Those planned to undergo TAVR, have prohibitive iliofemoral disease, and otherwise considered for alternative access, will be considered for the study. The medical devices being used are in the post-market stage as it is being used in accordance with its approved labeling, treating iliofemoral disease.
Study data will be recorded prospectively on dedicated Data Collection Forms and stored locally in a secure format. De-identified data will be uploaded for statistical analysis. IRB approval for the study will be obtained.
Eligibility
Inclusion Criteria:
- Age 18 to 90 years of age, inclusive, at the time of signing the informed consent
- Iliofemoral disease warrants treatment, per routine guidelines (greater than 50% stenosis and heavy calcification of the iliac's).
- Severe symptomatic aortic stenosis and undergoing a planned TAVR procedure
- Prohibitive iliofemoral disease, as determined by the diagnostic CT abdomen and pelvis.
- Subjects can provide written, informed consent.
Exclusion Criteria:
- Subject is participating in another research study involving an investigational agent that has not reached the primary endpoint.
- Subject who has contraindications to IVL
- Subject who has contraindications or is not eligible for TAVR